Congestive Heart Failure - Pipeline Review -





Published: October 2013 | Pages: 265 | Format: PDF

 Summary 

 Global Markets Direct’s, 'Congestive Heart Failure (Heart Failure) - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Congestive Heart Failure (Heart Failure), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Congestive Heart Failure (Heart Failure). Congestive Heart Failure (Heart Failure) - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. 

 Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. 

 Scope 

 

  •  A snapshot of the global therapeutic scenario for Congestive Heart Failure (Heart Failure). 
  •  A review of the Congestive Heart Failure (Heart Failure) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. 
  •  Coverage of products based on various stages of development ranging from discovery till registration stages. 
  •  A feature on pipeline projects on the basis of monotherapy and combined therapeutics. 
  •  Coverage of the Congestive Heart Failure (Heart Failure) pipeline on the basis of route of administration and molecule type. 
  •  Key discontinued pipeline projects. 
  •  Latest news and deals relating to the products. 

 

 Reasons to buy 

 

  •  Identify and understand important and diverse types of therapeutics under development for Congestive Heart Failure (Heart Failure). 
  •  Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. 
  •  Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. 
  •  Devise corrective measures for pipeline projects by understanding Congestive Heart Failure (Heart Failure) pipeline depth and focus of Indication therapeutics. 
  •  Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. 
  •  Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline. 

 

 Additional Information 

 Companies Mentioned 

 Bristol-Myers Squibb Company 

 Aastrom Biosciences, Inc. 

 Johnson & Johnson 

 Amgen Inc. 

 AstraZeneca PLC 

 Athersys, Inc. 

 GlaxoSmithKline plc 

 Gilead Sciences, Inc. 

 Merck & Co., Inc. 

 Bioheart, Inc. 

 Neurocrine Biosciences, Inc. 

 Novartis AG 

 Acorda Therapeutics, Inc. 

 Dong-A Pharmaceutical Co., Ltd. 

 Les Laboratoires Servier 

 Bayer AG 

 Celladon Corporation 

 IntelGenx Technologies Corp. 

 Mesoblast Ltd 

 Palatin Technologies, Inc. 

 Cardio3 BioSciences SA 

 La Jolla Pharmaceutical Company 

 ADVENTRX Pharmaceuticals 

 NeoStem, Inc. 

 Cytomedix, Inc. 

 POZEN Inc. 

 Torrent Pharmaceuticals Limited 

 AcelleRX Therapeutics Inc. 

 AngioDesign 

 NormOxys, Inc. 

 Cardioxyl Pharmaceuticals, Inc. 

 INNOPHARMAX, INC. 

 ARCA biopharma, Inc. 

 Glucox Biotech 

 Asklepios BioPharmaceutical, Inc. 

 Medistem, Inc. 

 Bial - Portela & Ca, S.A. 

 Sorbent Therapeutics, Inc. 

 Target Heart Biotec Srl 

 RegenoCELL Therapeutics, Inc. 

 Cellmid Ltd 

 PharmaIN Corporation 

 Country 

 Global 

 Sector 

 Cardiovascular 

 Introduction 

 Global Markets Direct Report Coverage 

 Congestive Heart Failure (Heart Failure) Overview 

 Therapeutics Development 

 An Overview of Pipeline Products for Congestive Heart Failure (Heart Failure) 

 Congestive Heart Failure (Heart Failure) Therapeutics under Development by Companies 

 Congestive Heart Failure (Heart Failure) Therapeutics under Investigation by Universities/Institutes 

 Late Stage Products 

 Comparative Analysis 

 Mid Clinical Stage Products 

 Comparative Analysis 

 Early Clinical Stage Products 

 Comparative Analysis 

 Discovery and Pre-Clinical Stage Products 

 Comparative Analysis 

 Congestive Heart Failure (Heart Failure) Therapeutics - Products under Development by Companies 

 Congestive Heart Failure (Heart Failure) Therapeutics - Products under Investigation by Universities/Institutes 

 Companies Involved in Congestive Heart Failure (Heart Failure) Therapeutics Development 

 Bristol-Myers Squibb Company 

 Aastrom Biosciences, Inc. 

 Johnson & Johnson 

 Amgen Inc. 

 AstraZeneca PLC 

 Athersys, Inc. 

 GlaxoSmithKline plc 

 Gilead Sciences, Inc. 

 Merck & Co., Inc. 

 Bioheart, Inc. 

 Neurocrine Biosciences, Inc. 

 Novartis AG 

 Acorda Therapeutics, Inc. 

 Dong-A Pharmaceutical Co., Ltd. 

 Les Laboratoires Servier 

 Bayer AG 

 Celladon Corporation 

 IntelGenx Technologies Corp. 

 Mesoblast Ltd 

 Palatin Technologies, Inc. 

 Cardio3 BioSciences SA 

 La Jolla Pharmaceutical Company 

 ADVENTRX Pharmaceuticals 

 NeoStem, Inc. 

 Cytomedix, Inc. 

 POZEN Inc. 

 Torrent Pharmaceuticals Limited 

 AcelleRX Therapeutics Inc. 

 AngioDesign 

 NormOxys, Inc. 

 Cardioxyl Pharmaceuticals, Inc. 

 INNOPHARMAX, INC. 

 ARCA biopharma, Inc. 

 Glucox Biotech 

 Asklepios BioPharmaceutical, Inc. 

 Medistem, Inc. 

 Bial - Portela & Ca, S.A. 

 Sorbent Therapeutics, Inc. 

 Target Heart Biotec Srl 

 RegenoCELL Therapeutics, Inc. 

 Cellmid Ltd 

 PharmaIN Corporation 

 Congestive Heart Failure (Heart Failure) - Therapeutics Assessment 

 Assessment by Monotherapy Products 

 Assessment by Route of Administration 

 Assessment by Molecule Type 

 Drug Profiles 

 alagebrium chloride - Drug Profile 

 MultiStem - Drug Profile 

 GRNCM-1 - Drug Profile 

 LCI-699 - Drug Profile 

 NBI-69734 - Drug Profile 

 ALD-201 - Drug Profile 

 PL-3994 - Drug Profile 

 naxifylline - Drug Profile 

 omecamtiv mecarbil - Drug Profile 

 ranolazine ER - Drug Profile 

 BIA-51058 - Drug Profile 

 ixmyelocel-T - Drug Profile 

 (enteric coated aspirin + immediate release omeprazole) - Drug Profile 

 DIPTA - Drug Profile 

 Mydicar - Drug Profile 

 CXL-1020 - Drug Profile 

 bucindolol hydrochloride - Drug Profile 

 cimaglermin alfa - Drug Profile 

 BNP-CHF - Drug Profile 

 CLP-1001 - Drug Profile 

 etomoxir - Drug Profile 

 JVS-100 - Drug Profile 

 C3BS-CQR-1 - Drug Profile 

 Allogeneic Mesenchymal Precursor Cells For Cardiovascular Disease - Drug Profile 

 MyoCell - Drug Profile 

 udenafil - Drug Profile 

 OXY-111A - Drug Profile 

 elinogrel potassium - Drug Profile 

 aliskiren fumarate - Drug Profile 

 C-Cure² - Drug Profile 

 JNJ-39588146 - Drug Profile 

 Nitroxyl Donor For CHF - Drug Profile 

 Allo-Cure - Drug Profile 

 oxypurinol - Drug Profile 

 COR-1 - Drug Profile 

 AMR-001 - Drug Profile 

 CTX-101 - Drug Profile 

 AZD-1722 - Drug Profile 

 CAMI-103 - Drug Profile 

 MK-7145 IR - Drug Profile 

 albuterol - Drug Profile 

 Human Atrial Natriuretic Peptide - Drug Profile 

 poloxamer - Drug Profile 

 ERC-124 - Drug Profile 

 PEG-Relaxin - Drug Profile 

 enoximone - Drug Profile 

 S-38844 - Drug Profile 

 LJPC-201 - Drug Profile 

 poloxamer - Drug Profile 

 poloxamer - Drug Profile 

 REC-02 - Drug Profile 

 SER-101 - Drug Profile 

 2nd Generation HNO Donor - Drug Profile 

 Recombinant Human Melusin - Drug Profile 

 FAD-286 - Drug Profile 

 BAY-1067197 - Drug Profile 

 BAY-868050 - Drug Profile 

 BAY-1021189 - Drug Profile 

 AntimiR-199a - Drug Profile 

 Drug For Heart Failure - Drug Profile 

 GSK-2849466 - Drug Profile 

 paroxetine - Drug Profile 

 TRC-4186 - Drug Profile 

 Gene Therapy For Ischemic Heart Failure - Drug Profile 

 AAV9-S100A1 - Drug Profile 

 AC-6 Gene Therapy - Drug Profile 

 piboserod hydrochloride - Drug Profile 

 aladorian - Drug Profile 

 CARD-024 - Drug Profile 

 Drug Acting On Beta-1 Adrenergic Receptor - Drug Profile 

 Isoxazoles - Drug Profile 

 MicroRNAs For Heart Failure - Drug Profile 

 Calpain Inhibitor - Drug Profile 

 Drug For Heart Failure - Drug Profile 

 Regenerative Medicine For Heart Failure - Drug Profile 

 JNJ-54452840 - Drug Profile 

 MonoCell - Drug Profile 

 Stromal Interaction Molecule 1 Inhibitor - Drug Profile 

 Drugs For Heart Failure - Drug Profile 

 UCF-101 - Drug Profile 

 Gene Therapy For Heart Failure - Drug Profile 

 Isopropylamine - Drug Profile 

 Relaxin Family Receptor-1 Agonists - Drug Profile 

 Serpinin - Drug Profile 

 Pyroglutaminated Serpinin - Drug Profile 

 Fenoterol Analogues - Drug Profile 

 AAV6.BetaARKct - Drug Profile 

 Beta3-Adrenoreceptor Inverse Agonists - Drug Profile 

 Therapy For End-Organ Damage - Drug Profile 

 Congestive Heart Failure (Heart Failure) Therapeutics - Drug Profile Updates 

 Congestive Heart Failure (Heart Failure) Therapeutics - Discontinued Products 

 Congestive Heart Failure (Heart Failure) Therapeutics - Dormant Products 

 Congestive Heart Failure (Heart Failure) - Product Development Milestones 

 Featured News & Press Releases 

 Appendix 

 Methodology 

 Coverage 

 Secondary Research 

 Primary Research 

 Expert Panel Validation 

 Contact Us 

 Disclaimer 

 List of Tables 

 Number of Products Under Development for Congestive Heart Failure (Heart Failure), H2 2013 

 Products under Development for Congestive Heart Failure (Heart Failure) - Comparative Analysis, H2 2013 

 Number of Products under Development by Companies, H2 2013 

 Number of Products under Development by Companies, H2 2013 (Contd..1) 

 Number of Products under Development by Companies, H2 2013 (Contd..2) 

 Number of Products under Development by Companies, H2 2013 (Contd..3) 

 Number of Products under Investigation by Universities/Institutes, H2 2013 

 Comparative Analysis by Late Stage Development, H2 2013 

 Comparative Analysis by Mid Clinical Stage Development, H2 2013 

 Comparative Analysis by Early Clinical Stage Development, H2 2013 

 Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2013 

 Products under Development by Companies, H2 2013 

 Products under Development by Companies, H2 2013 (Contd..1) 

 Products under Development by Companies, H2 2013 (Contd..2) 

 Products under Development by Companies, H2 2013 (Contd..3) 

 Products under Development by Companies, H2 2013 (Contd..4) 

 Products under Investigation by Universities/Institutes, H2 2013 

 Bristol-Myers Squibb Company, H2 2013 

 Aastrom Biosciences, Inc., H2 2013 

 Johnson & Johnson, H2 2013 

 Amgen Inc., H2 2013 

 AstraZeneca PLC, H2 2013 

 Athersys, Inc., H2 2013 

 GlaxoSmithKline plc, H2 2013 

 Gilead Sciences, Inc., H2 2013 

 Merck & Co., Inc., H2 2013 

 Bioheart, Inc., H2 2013 

 Neurocrine Biosciences, Inc., H2 2013 

 Novartis AG, H2 2013 

 Acorda Therapeutics, Inc., H2 2013 

 Dong-A Pharmaceutical Co., Ltd., H2 2013 

 Les Laboratoires Servier, H2 2013 

 Bayer AG, H2 2013 

 Celladon Corporation, H2 2013 

 IntelGenx Technologies Corp., H2 2013 

 Mesoblast Ltd, H2 2013 

 Palatin Technologies, Inc., H2 2013 

 Cardio3 BioSciences SA, H2 2013 

 La Jolla Pharmaceutical Company, H2 2013 

 ADVENTRX Pharmaceuticals, H2 2013 

 NeoStem, Inc., H2 2013 

 Cytomedix, Inc., H2 2013 

 POZEN Inc., H2 2013 

 Torrent Pharmaceuticals Limited, H2 2013 

 AcelleRX Therapeutics Inc., H2 2013 

 AngioDesign, H2 2013 

 NormOxys, Inc., H2 2013 

 Cardioxyl Pharmaceuticals, Inc., H2 2013 

 INNOPHARMAX, INC., H2 2013 

 ARCA biopharma, Inc., H2 2013 

 Glucox Biotech, H2 2013 

 Asklepios BioPharmaceutical, Inc., H2 2013 

 Medistem, Inc., H2 2013 

 Bial - Portela & Ca, S.A., H2 2013 

 Sorbent Therapeutics, Inc., H2 2013 

 Target Heart Biotec Srl, H2 2013 

 RegenoCELL Therapeutics, Inc., H2 2013 

 Cellmid Ltd, H2 2013 

 PharmaIN Corporation, H2 2013 

 Assessment by Monotherapy Products, H2 2013 

 Assessment by Stage and Route of Administration, H2 2013 

 Assessment by Stage and Molecule Type, H2 2013 

 Congestive Heart Failure (Heart Failure) Therapeutics - Drug Profile Updates 

 Congestive Heart Failure (Heart Failure) Therapeutics - Discontinued Products 

 Congestive Heart Failure (Heart Failure) Therapeutics - Dormant Products 

 Congestive Heart Failure (Heart Failure) Therapeutics - Dormant Products (Contd..1) 

 Congestive Heart Failure (Heart Failure) Therapeutics - Dormant Products (Contd..2) 

 Congestive Heart Failure (Heart Failure) Therapeutics - Dormant Products (Contd..3) 

 List of Figures 

 Number of Products under Development for Congestive Heart Failure (Heart Failure), H2 2013 

 Products under Development for Congestive Heart Failure (Heart Failure) - Comparative Analysis, H2 2013 

 Products under Development by Companies, H2 2013 

 Products under Investigation by Universities/Institutes, H2 2013 

 Late Stage Products, H2 2013 

 Mid Clinical Stage Products, H2 2013 

 Early Clinical Stage Products, H2 2013 

 Discovery and Pre-Clinical Stage Products, H2 2013 

 Assessment by Monotherapy Products, H2 2013 

 Assessment by Route of Administration, H2 2013 

 Assessment by Stage and Route of Administration, H2 2013 

 Assessment by Molecule Type, H2 2013 

 Assessment by Stage and Molecule Type, H2 2013